Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02897557 · ClinicalTrials.gov registry record · NA
Insulet Artificial Pancreas Early Feasibility Study
A NA study of Type 1 Diabetes, sponsored by Insulet Corporation.
- Completed
- Registry status
- NA
- Development phase
- 59
- Enrollment target
- 4
- Study locations
NCT02897557: Completed NA study of Type 1 Diabetes, sponsored by Insulet Corporation.
NCT02897557 is a NA study of Type 1 Diabetes that has completed, run by Insulet Corporation. The registered enrollment target is 59 participants, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (92% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02897557, a NA study of Type 1 Diabetes, has completed, sponsored by Insulet Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
- 59 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose is to perform an early investigation on the safety and performance of an Automated Glucose Control (AGC) algorithm using the OmniPod® Insulin Management System and gather clinical data that will be used to make improvements or modifications to the algorithm for subsequent studies in adults, adolescents and children with type 1 diabetes.
Conditions Studied
Interventions
- DEVICE Insulet Artificial Pancreas (AP) System
Study Locations (4)
California
- Stanford University - Palo Alto
- William Sansum Diabetes Center - Santa Barbara
- Diablo Clinical Research - Walnut Creek
Colorado
- University of Colorado Denver - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2016-09 |
| Est. Completion | 2017-03 |
| Phase | NA |
What the finished NCT02897557 record still lists
NCT02897557 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 766-participant average among 198 other Type 1 Diabetes trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Insulet Artificial Pancreas (AP) System is the first listed.
NCT02897557 reports a single indexed study location in California, Colorado.
Frequently Asked Questions
What is clinical trial NCT02897557 about?
NCT02897557 is a clinical study titled "Insulet Artificial Pancreas Early Feasibility Study". The purpose is to perform an early investigation on the safety and performance of an Automated Glucose Control (AGC) algorithm using the OmniPod® Insulin Management System and gather clinical data that will be used to make improvements or modifications to the algorithm for subsequent studies in adul...
What is the current status of trial NCT02897557?
This trial is currently completed. It is a NA study. The enrollment target is 59 participants. The study started on 2016-09. Estimated completion is 2017-03.
What conditions does trial NCT02897557 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT02897557?
The interventions under investigation include: Insulet Artificial Pancreas (AP) System (DEVICE).
Who is sponsoring clinical trial NCT02897557?
This trial is sponsored by Insulet Corporation, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02897557 being conducted?
This trial has 4 study locations across California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02897557's enrollment target sits among peer trials
59 83rd of 198 higher than 115 of 198 other Type 1 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 1 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
REAL-Fam Feasibility Study for Youth Diabetes Management
RECRUITING · NA
-
AIDANET Pediatrics
RECRUITING · NA
-
A Study Comparing Dexcom Continuous Glucose Monitoring to Point of Care Glucose Testing for the Management of Hospital and Post-Discharge Subjects With Type 1 Diabetes
RECRUITING · NA
-
Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 Diabetes Using Automated Insulin Delivery
RECRUITING · NA
-
EMPoWER Study - Strengths-based Behavioral Intervention for Youth With Type 1 Diabetes
RECRUITING · NA
-
Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia